NLRP3 and familial dilated cardiomyopathy: Treatment with RVS resulted in a 52% reduction in NLRP3 levels and a 28% decrease in IL-1β content, while PTS led to an even greater suppression of NLRP3 levels (62%) and a 24% reduction in IL-1β content relative to the untreated DCM group.